Pfizer Retained Earnings (Accumulated Deficit) 2010-2024 | PFE
Pfizer retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Pfizer retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $121.059B, a 4.23% decline year-over-year.
- Pfizer retained earnings (accumulated deficit) for 2023 were $118.353B, a 5.81% decline from 2022.
- Pfizer retained earnings (accumulated deficit) for 2022 were $125.656B, a 21.53% increase from 2021.
- Pfizer retained earnings (accumulated deficit) for 2021 were $103.394B, a 14.38% increase from 2020.
Pfizer Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$118,353 |
| 2022 |
$125,656 |
| 2021 |
$103,394 |
| 2020 |
$90,392 |
| 2019 |
$97,670 |
| 2018 |
$89,554 |
| 2017 |
$85,291 |
| 2016 |
$71,774 |
| 2015 |
$71,993 |
| 2014 |
$72,176 |
| 2013 |
$69,732 |
| 2012 |
$54,240 |
| 2011 |
$46,210 |
| 2010 |
$42,716 |
| 2009 |
$40,426 |
Pfizer Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$121,059 |
| 2024-06-30 |
$116,596 |
| 2024-03-31 |
$121,318 |
| 2023-12-31 |
$118,353 |
| 2023-09-30 |
$126,411 |
| 2023-06-30 |
$128,796 |
| 2023-03-31 |
$131,102 |
| 2022-12-31 |
$125,656 |
| 2022-09-30 |
$122,967 |
| 2022-06-30 |
$116,608 |
| 2022-03-31 |
$111,193 |
| 2021-12-31 |
$103,394 |
| 2021-09-30 |
$102,252 |
| 2021-06-30 |
$96,346 |
| 2021-03-31 |
$95,158 |
| 2020-12-31 |
$90,392 |
| 2020-09-30 |
$100,284 |
| 2020-06-30 |
$100,203 |
| 2020-03-31 |
$101,000 |
| 2019-12-31 |
$97,670 |
| 2019-09-30 |
$100,113 |
| 2019-06-30 |
$94,440 |
| 2019-03-31 |
$93,388 |
| 2018-12-31 |
$89,554 |
| 2018-09-30 |
$91,995 |
| 2018-06-30 |
$89,860 |
| 2018-03-31 |
$89,961 |
| 2017-12-31 |
$85,291 |
| 2017-09-30 |
$75,043 |
| 2017-06-30 |
$74,107 |
| 2017-03-31 |
$74,847 |
| 2016-12-31 |
$71,774 |
| 2016-09-30 |
$72,846 |
| 2016-06-30 |
$73,350 |
| 2016-03-31 |
$74,971 |
| 2015-12-31 |
$71,993 |
| 2015-09-30 |
$74,019 |
| 2015-06-30 |
$73,620 |
| 2015-03-31 |
$74,471 |
| 2014-12-31 |
$72,176 |
| 2014-09-30 |
$74,292 |
| 2014-06-30 |
$71,627 |
| 2014-03-31 |
$72,028 |
| 2013-12-31 |
$69,732 |
| 2013-09-30 |
$70,381 |
| 2013-06-30 |
$67,628 |
| 2013-03-31 |
$56,972 |
| 2012-12-31 |
$54,240 |
| 2012-09-30 |
$51,256 |
| 2012-06-30 |
$47,904 |
| 2012-03-31 |
$48,124 |
| 2011-12-31 |
$46,210 |
| 2011-09-30 |
$48,121 |
| 2011-06-30 |
$44,320 |
| 2011-03-31 |
$44,926 |
| 2010-12-31 |
$42,716 |
| 2010-09-30 |
$42,873 |
| 2010-06-30 |
$42,010 |
| 2010-03-31 |
$42,429 |
| 2009-12-31 |
$40,426 |
| 2009-09-30 |
$54,835 |
| 2009-06-30 |
$51,965 |
| 2009-03-31 |
$51,863 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
